Clareon PanOptix Pro — How the New Trifocal IOL Compares to the Original PanOptix

The PanOptix trifocal IOL from Alcon has been the most widely implanted premium lens in its category worldwide, with more than three million lenses implanted globally. The original platform received the Prix Galien Award in 2021 in recognition of its clinical impact on spectacle independence after cataract surgery. Alcon has now replaced it with the Clareon PanOptix Pro, incorporating ENLIGHTEN NXT optical technology. In this post I want to explain what changed, what the current evidence actually shows, and what this means for patients considering a trifocal IOL in Australia, or optometrists counselling patients before referral. For a broader overview of all premium lens categories available in Australia, see the Premium IOL Guide Australia 2026.

Why the original PanOptix became the reference standard

The original PanOptix, implanted on the Clareon hydrophobic acrylic platform, delivered three discrete focal points: distance, approximately 60cm for intermediate tasks such as computer use, and approximately 40cm for near tasks including reading. It used ENLIGHTEN optical technology to direct 88 percent of incoming light to these three focal zones, with the remaining 12 percent scattered rather than directed to useful vision. The Clareon hydrophobic acrylic material produces virtually no glistenings and has a low rate of posterior capsule opacification, both meaningful practical advantages over earlier IOL platform materials. For patients and optometrists who want to understand how trifocals work as a category alongside other multifocal IOLs, the optical principles are described in detail on the multifocal IOL page.

The evidence base that accumulated for the original PanOptix was substantial. A meta-analysis by Sudhir and colleagues analysing more than six prospective studies found spectacle independence rates above 85 percent for the large majority of daily activities. A worldwide pooled outcomes analysis by Kohnen and colleagues published in Clinical Ophthalmology in 2023 found consistent visual acuity and patient-reported outcomes across geographically diverse surgical centres. These are the data that established the PanOptix platform as a trusted clinical choice before the Pro iteration was introduced.

The known limitation of the original PanOptix, as with all diffractive trifocal lenses, was halos and glare around point light sources at night. These are caused by the concentric diffractive rings that create the three focal points. The severity and tolerability of this effect varies considerably between patients and typically diminishes over a neuroadaptation period of three to six months. Patient selection and pre-operative counselling were, and remain, the most important determinants of outcome with any trifocal IOL.

What ENLIGHTEN NXT technology changes

The Clareon PanOptix Pro introduces ENLIGHTEN NXT, the second-generation version of the platform's optical technology. The principal changes, as reported by Alcon from optical bench testing and vision simulator studies, are as follows. Light utilisation is improved from 88 percent to 94 percent, which Alcon reports is the highest figure for any trifocal IOL currently available. The corollary is that light scatter is reduced from 12 percent to 6 percent — a 50 percent reduction. Optical image contrast between the distance and intermediate focal zones is improved by 16 percent. Alcon describes the result as uninterrupted light distribution across the full visual range, reducing the optical interference at the transitions between focal zones that contributes to halos in the original design.

What has not changed: the focal points are identical. Distance vision, intermediate vision at approximately 60cm, and near vision at approximately 40cm are retained from the original. The Clareon hydrophobic acrylic material is unchanged. A toric correction version, the Clareon PanOptix Pro Toric, corrects corneal astigmatism simultaneously with the trifocal correction. The lens is available in the AutonoMe preloaded disposable delivery system as well as the traditional Monarch IV injector. FDA approval was granted in 2023 and the lens launched commercially in the United States in 2025. It is now available in Australia.

What the evidence shows — an honest assessment

This is the section I want to be particularly careful about, because there is a meaningful difference between manufacturer bench data and independent peer-reviewed clinical outcomes, and patients and optometrists deserve clarity about which category the current evidence falls into.

Alcon completed two contralateral studies comparing the PanOptix Pro and original PanOptix, registered on ClinicalTrials.gov as NCT06400745 (Study A) and NCT06401551 (Study B). In a contralateral study design, one eye receives the Pro and the other receives the original PanOptix in the same patient, allowing direct within-patient comparison of the two lenses. These studies were completed in April 2025 and results were posted in December 2025. The primary endpoint was non-inferiority of distance visual acuity for the Pro versus the original, confirming that the new version does not compromise the distance vision already well-established with the original platform. These trials were Alcon-sponsored and industry-conducted, and as of mid-2026 the full datasets have not been published in a peer-reviewed journal.

The performance improvements for ENLIGHTEN NXT are currently based primarily on optical bench testing and vision simulator studies. The optical improvement from reduced light scatter is grounded in sound physics and there is a clear mechanistic basis to expect that 94 percent light utilisation versus 88 percent will translate to reduced halo intensity in clinical practice. However, independent peer-reviewed head-to-head data comparing patient-reported dysphotopsia rates and satisfaction scores between the Pro and original PanOptix remains awaited. The AAO EyeWiki acknowledges the Pro as designed to reduce light scatter versus the original. The original PanOptix defocus curve demonstrated consistent visual acuity from approximately +0.50 dioptres to -3.0 dioptres of defocus, and the Pro is expected to maintain this range. Early experience among surgeons following the US commercial launch in 2025 is consistent with what the bench data predicts: a similar visual range to the original, with improved light handling characteristics.

How PanOptix Pro compares to other premium lens categories

For a detailed analysis of how trifocal lenses compare to non-diffractive EDOF and hybrid lens categories, including visual acuity data and dysphotopsia profiles from published studies, see the full range of vision IOL guide. The summary most relevant to patients considering PanOptix Pro specifically is as follows.

Compared with non-diffractive EDOF lenses such as the Clareon Vivity or TECNIS PureSee, PanOptix Pro provides a stronger discrete near focal point at approximately 40cm. This means higher spectacle independence for close reading tasks. The trade-off is a higher rate of halos and glare, particularly during the three to six month neuroadaptation period. EDOF lenses provide excellent distance and intermediate vision with a dysphotopsia profile approaching monofocal equivalence. Patients who drive frequently at night, have occupational requirements for low-light vision, or who express concern about visual side effects before surgery are generally better served by a non-diffractive EDOF than a trifocal, regardless of which trifocal iteration is offered.

Compared with enhanced monofocal lenses such as the TECNIS Eyhance or Rayner RayOne EMV, PanOptix Pro offers significantly greater spectacle independence but introduces the dysphotopsias inherent in diffractive optics. Enhanced monofocals provide a modest extension of intermediate range with a dysphotopsia profile indistinguishable from a standard monofocal, and remain the appropriate choice for patients who prioritise optical quality and night vision safety above spectacle independence, or who have conditions such as mild macular pathology, previous LASIK, or significant dry eye that contraindicate diffractive optics.

Good candidates for PanOptix Pro are patients who are highly motivated to reduce glasses dependence for near tasks, have healthy maculas and regular corneas, have a well-controlled ocular surface, and can realistically accept a neuroadaptation period of three to six months during which halos around night lights are most noticeable. Patients with large mesopic pupils, pre-existing reduction in contrast sensitivity, macular pathology, keratoconus or irregular corneal topography, or significant dry eye disease are generally not trifocal candidates, regardless of which generation of the platform is used. Patients with previous LASIK require modified IOL power calculation and individual assessment of whether diffractive optics are appropriate given the altered corneal profile.

Mix-and-match: PanOptix Pro with Clareon Vivity

Contralateral implantation of Clareon PanOptix Pro in the non-dominant eye and Clareon Vivity in the dominant eye has attracted interest as a strategy for achieving broader spectacle independence while limiting dysphotopsias in the dominant eye. Both lenses share the Clareon hydrophobic acrylic platform, including material properties, edge design, chromophore, and A-constant, which may support binocular integration. A dedicated randomised study of this combination has been registered as NCT07076277 at the Shafer Vision Institute, with results expected in December 2026. At present the approach is based on clinical experience and platform consistency rationale rather than published trial data, and should be framed for patients as such.

My current practice

I now implant the Clareon PanOptix Pro as my preferred trifocal IOL at Northern Eye Consultants in Bundoora. The optical improvements in the Pro are grounded in sound engineering and the mechanistic basis for reduced halo intensity with 94 percent light utilisation is clear. I expect the bench improvements to translate meaningfully in clinical practice as independent data accumulates. However, the shift from original to Pro does not change my patient selection criteria. The most important determinant of outcome with any diffractive trifocal remains the quality of pre-operative assessment and the care taken in identifying patients for whom this lens category is appropriate.

A patient who understands the neuroadaptation period before surgery, has a healthy macula and regular cornea, has optimised their ocular surface, and is genuinely motivated by near reading independence does well with trifocal lenses. A patient who is anxious about night vision before surgery, drives frequently in the dark, or has early macular change is better served by a non-diffractive EDOF or enhanced monofocal, regardless of which trifocal generation is available. Optometrists referring patients for premium IOL assessment help most by documenting macular OCT, ocular surface status, and a clear description of the patient's visual priorities and night-driving requirements.

For a full reference on cataract surgery and all lens categories, see the cataract surgery section of this site. For information on my approach to cataract surgery including surgical experience and training, see cataract surgery at drmacintyre.com.

References

1. Sudhir RR, et al. Comparative meta-analysis of trifocal IOL outcomes: spectacle independence and dysphotopsia profiles across prospective studies of the PanOptix platform.
2. Kohnen T, et al. Worldwide clinical outcomes of the AcrySof IQ PanOptix trifocal intraocular lens. Clin Ophthalmol. 2023.
3. Alcon. CLAREON PanOptix Pro contralateral study NCT06400745 (Study A). ClinicalTrials.gov. Results posted December 2025.
4. Alcon. CLAREON PanOptix Pro contralateral study NCT06401551 (Study B). ClinicalTrials.gov. Results posted December 2025.
5. EyeWiki (American Academy of Ophthalmology). Trifocal intraocular lenses. AAO EyeWiki. 2026.
6. Shafer Vision Institute. NCT07076277: Contralateral study of Clareon PanOptix Pro and Clareon Vivity. ClinicalTrials.gov. Results expected December 2026.